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Available online 17 March 2016A 63-year-old woman presented with severe headache
and back pain ongoing for 1 day. Computed tomography
(CT) of the head revealed multiple bony low densities in
the skull, and a bony lytic destruction involving the upper
clivus area on the left side with association of a 1.2-cm mass
lesion against the left cavernous sinus and left carotid
canal. Magnetic resonance imaging of the head confirmed
the presence of multiple lesions of abnormal signal and
enhancement throughout the calvarium and base of the cli-
vus and lesions of abnormal signal within C1–C3 vertebral
bodies. A skeletal survey showed the skull lytic lesions as
well as an expansile lesion in the right eighth rib and a
prominent right mediastinal contour. CT of the chest and
dorsal spine disclosed lytic expansile skeletal metastatic
lesions involving the right lateral eighth rib, T1, T2, T6,
T8, and T11 vertebral bodies, with associated severe ante-rior wedge compression pathological fractures involving
the T6 and T11 vertebral bodies and evidence for spinal
canal tumor invasion. There was also bulky, malignant
appearing, mediastinal lymphadenopathy measuring
5.8 cm and enlarged lymph nodes in the base of the right
anterior neck/thoracic inlet region measuring 4.8 cm. Com-
plete blood count and serum biochemistry were unremark-
able. Lactate dehydrogenase (LDH) was found significantly
elevated at 592 IU/L. Serum and urine electrophoresis with
immunofixation revealed monoclonal-kappa immunoglobu-
lins. Bone marrow aspiration and biopsy failed to identify
any sheets or clusters of atypical cells, blasts, or plasma
cells. CT-guided bone biopsy of the right eighth rib lesion
only showed lymphoplasmacytic and neutrophilic exudates
with fragments of soft tissue and crush artifact, which was
nondiagnostic. Finally, the patient underwent medi-
astinoscopy with biopsy of the right paratracheal mass
which showed lymphohistiocytic infiltrates and nests of
atypical plasma cells (Figure 1A). Immunohistochemical
analysis revealed diffuse positivity for CD138 (Figure 1B)
and cytoplasmic-kappa chains (Figure 1C), comprising 65%
of the cell population. Cytoplasmic lambda-positive cells
Figure 1 (A) Hematoxylin and eosin stain at high power (40) showing nests of atypical plasma cells, occasionally with eccentric
nuclei. Immunohistochemical staining showed: (B) diffuse positivity for CD138; (C) cytoplasmic kappa; and (D) cytoplasmic lambda
light chains.
Dual Light Chain Extramedullary Myeloma 163(5% of cells) were also noted (Figure 1D). The patient was
started on dexamethasone and bortezomib and also
received palliative radiotherapy to the spine, with relief
of her back pain. Three months after initial diagnosis,
reimaging with contrast-enhanced CT of the chest, abdo-
men, and pelvis disclosed stable mediastinal and right infr-
aclavicular lymphadenopathy, and unchanged multilevel
lytic lesions in the thoracic and lumbar spine, right humeral
head, right scapula, and right ribs. However, small nonoc-
clusive pulmonary emboli were found in the right middle
and right lower lobe pulmonary artery branches, and also
thrombosis of the right gonadal vein.
The frequency of dual kappa and lambda light chain pro-
duction observed in plasma cell myeloma is similar to that in
normal B-cells, and is 0.5–2% [1]. Secretion of only kappa
light chain in our case indicates that nonsecreting light
chain may not be functionally active.
Extramedullary disease (EMD) is an uncommon manifes-
tation at the time of diagnosis of multiple myeloma, with
an incidence of 2.4–4.5% [2]. Patients who initially present
with EMD are less likely to have Stage I Durie–Salmon, as
they frequently have more than three lytic bone lesions
[3]. In addition, consistent with our case, an association
between elevated LDH levels and extraosseous disease has
been described [2,4]. Among patients who present with
EMD at the time of diagnosis, the 5-year overall survival
was found to be significantly lower compared with patients
with classical bone marrow-confined myeloma (31% vs. 59%)
and progression-free survival at 5 years was alsosignificantly lower (21% vs. 50%) [2], although bortezomib
has shown activity in EMD [5]. A benefit from a high-dose
melphalan-based or pomalidomide-based chemotherapeutic
regimen has also been supported [6,7]. In our case,
performance status and abnormal renal function were
limiting factors to more aggressive upfront therapy.Conflicts of interest
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